Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acamprosate
Drug ID BADD_D00016
Description Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity, and increased healthcare spending.[A229073] Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. It is a structural analogue of the neurotransmitter γ-aminobutyric acid (GABA).[L31758] Acamprosate is the first medication specifically formulated for the maintenance of alcohol abstinence in ethanol-dependent patients after alcohol detoxification[A997], unlike [naltrexone] and [disulfiram]. It was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783]
Indications and Usage For the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation
Marketing Status Prescription; Discontinued
ATC Code N07BB03
DrugBank ID DB00659
KEGG ID D07058
MeSH ID D000077443
PubChem ID 71158
TTD Drug ID D0GC2M
NDC Product Code Not Available
Synonyms Acamprosate | Acamprostate | N-Acetylhomotaurine | N Acetylhomotaurine | Campral EC | N-Acetylhomotaurine, Magnesium (2:1) Salt | N-Acetylhomotaurine, Monolithium Salt | N Acetylhomotaurine, Monolithium Salt | N-Acetylhomotaurine, Zinc (2:1) Salt | Campral | N-Acetylhomotaurine, Monosodium Salt | N Acetylhomotaurine, Monosodium Salt | Sodium Acetylhomotaurine | Acetylhomotaurine, Sodium | Zulex | Acamprosate Calcium | Calcium Acetylhomotaurine | Acetylhomotaurine, Calcium | Calcium Acetylhomotaurinate | Acetylhomotaurinate, Calcium | N-Acetylhomotaurine, Calcium (2:1) Salt | Calcium Acetyl Homotaurinate | Acetyl Homotaurinate, Calcium | N-Acetylhomotaurine, Monopotassium Salt | N Acetylhomotaurine, Monopotassium Salt | Aotal | Regtect
Chemical Information
Molecular Formula C5H11NO4S
CAS Registry Number 77337-76-9
SMILES CC(=O)NCCCS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Multiple fractures12.04.02.009; 15.08.02.005--Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005--Not Available
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.009--
Myopathy15.05.05.001--Not Available
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nephrolithiasis20.04.01.002--
Nervousness19.06.02.003--Not Available
Neuralgia17.02.07.005--
Neurosis19.06.01.001--Not Available
Nocturia20.02.03.001--Not Available
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Oesophagitis07.08.05.001--
Orthostatic hypotension17.05.01.020; 24.06.03.004--Not Available
Pain08.01.08.004--
Palpitations02.01.02.003--
Pancreatitis07.18.01.001--
Panophthalmitis06.04.05.005--Not Available
Paraesthesia17.02.06.005--
Paranoia19.05.01.005--Not Available
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
Phlebitis12.02.01.002; 24.05.03.001--
Photophobia06.01.01.004; 17.17.02.006--
Photosensitivity reaction23.03.09.003--
Pneumonia11.01.09.003; 22.07.01.003--Not Available
Pollakiuria20.02.02.007--
Polyuria20.02.03.002--Not Available
Pruritus23.03.12.001--
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages